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Abstract
Introduction: Primary Ewing’s sarcoma or primitive neuroectodermal tumor of the genital tract of women is
uncommon. Rarer still is its occurrence in the vagina, with only five cases described so far. Out of these, only one
case was confirmed using molecular analysis.
Case presentation: We present an extremely rare case of Ewing’s sarcoma or primitive neuroectodermal tumor in
a 17-year-old Indian girl. She presented with a vaginal mass that was initially diagnosed as a malignant round cell
tumor. Immunohistochemistry showed diffuse positivity for vimentin, membranous positivity for MIC2, and
positivity for BCL2 and FLI-1. On the other hand, she was negative for cytokeratin, epithelial membrane antigen,
desmin, Myo D-1, myogenin and smooth muscle actin. A diagnosis of primitive neuroectodermal tumor was thus
offered. Furthermore, a molecular analysis of our patient using reverse transcription-polymerase chain reaction
technique showed positivity for t(11; 22) (q24; q12) (EWSR1-FLI1), thus confirming the diagnosis of a Ewing’s
sarcoma/primitive neuroectodermal tumor. Our patient was offered chemotherapy on Institutional protocol EFT
2001.
Conclusion: This is a rare case of primary vaginal Ewing’s sarcoma or primitive neuroectodermal tumor, which was
confirmed with molecular analysis, in the youngest patient known so far. This study reinforces the value of
integrating morphological features with membranous MIC2 positivity, along with application of molecular
techniques in objective identification of an Ewing’s sarcoma or primitive neuroectodermal tumor at uncommon
sites.
Introduction
Primary extraosseous Ewing’s sarcoma, also called primi-
tive neuroectodermal tumor (PNET) is uncommonly
documented as occurring in the genital tract of women,
such as the uterine corpus, the cervix and the ovary [1-3].
The vagina is a rare site for the occurrence of a primary
Ewing’s sarcoma and/or PNET, with only five cases docu-
mented so far, including a single case confirmed with
m o l e c u l a ra n a l y s i s[ 4 - 8 ] .W ep r e s e n tac a s eo fv a g i n a l
Ewing’s sarcoma or PNET occurring as a rare tumor
diagnosed in a 17-year-old girl. It reinforces the value of
molecular analysis preceded by histomorphology and
immunohistochemistry (IHC) in objectively confirming
the presence of specific sarcomas at unusual sites.
Case presentation
A 17-year-old girl from central India presented with
complaints of whitish, foul-smelling vaginal discharge
with fragmented bits that she had been experiencing for
a year prior to presentation. She had no history of any
associated vaginal bleeding. Prior to presentation, she
underwent alternative treatment but the symptoms had
persisted. A month before she presented to our hospital,
she was referred to us with acute urinary retention. She
was catheterized. Her clinical examination showed that
her general condition was fair. She had a Foley’s cathe-
ter in situ and an enlarged uterus with pyometra. She * Correspondence: rekhi.bharat@gmail.com
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gical investigations.
Her laboratory findings are as follows: low haemoglo-
bin (Hb) level at 9 g/dl, low red blood cell count (RBC)
at 3.32 (normal = 3.8 to 4.8 × 10 e12/L); low haemoato-
crit at 26.8% (normal = 36% to 46%); low mean corpus-
cular volume (MCV) at 80.0 (normal = 83 to 10/FL).
Meanwhile, her C-reactive protein value was high at
8.54 mg/dl (normal= < 1 mg/dl). She also had high
serum lactate dehydrogenase (242 U/L) and alkaline
phosphatase levels.
Our patient also underwent radiological investigations.
Her magnetic resonance imaging (MRI) showed a soft tis-
sue mass involving her anterior and posterior vaginal
walls and her anterior sacrum. Her urinary bladder was
displaced anteriorly. The mass was hyperintense on
T2-weighted and hypointense on T1-weighted imaging.
She had no pelvic lymphadenopathy. Her ureters were
also identified along with her visualized bones. Her chest
X-ray revealed no abnormality.
A computed tomography (CT) of her thorax showed a
sub-centimeter-sized mediastinal node and multiple
nodules in her bilateral lung parenchyma and subpleural
location. Her pleural spaces, heart, great vessels, and
bilateral bronchi were normal.
Her abdominal CT showed bilateral kidneys with pres-
sure changes and with dilated ureters. Her other organs
and biliary tree were normal. No lymphadenopathy was
identified.
Her pelvic CT scan revealed a heterogeneously
enhanced mass measuring 10 × 9.8 × 9 cm that involved
her vagina and caused a narrowing of her cervix. Her
cervix was also dilated with fluid and air. The mass was
seen as extending up to her introitus and involving her
perineum. As a result, her urinary bladder was pushed
anteriorly towards the right side. Bilateral adnexae were
noted with no ascites or any associated lymphadenopa-
thy (Figure 1). An ultrasonography showed haematome-
tra and minimal fluid in her pelvis with septations, apart
from the vaginal mass. A biopsy of the vaginal mass was
then performed. Her biopsy material was subjected to
formalin-fixed, paraffin-embedded tissue sections that
were stained with conventional haematoxylin and eosin
(H & E) staining. IHC was carried out on formalin-
fixed, paraffin-embedded tissue using the polymer tech-
nique (Biocare Med, MACH2 Universal polymer detec-
tion). The various antibodies used were vimentin
(monoclonal, 1:50, Dako, Produkionsveg, Glostrup, Den-
mark), MIC2/CD99, cytokeratin (CK) (monoclonal,
1:100, Dako), epithelial membrane antigen (EMA)
(monoclonal, 1:100, Dako), BCL2 (1:50, monoclonal,
Dako), FLI-1 (1:75, polyclonal, Biocare Med, USA), des-
min (monoclonal, 1:50, Dako), Myo D-1 (monoclonal,
1:20, Dako), Myogenin (1:50, Novocastra, UK) and
smooth muscle actin (SMA) (monoclonal, 1:20, Dako).
Biopsy material from our patient was then submitted
for molecular analysis using ribonucleic acid (RNA) iso-
lation and reverse transcription polymerase chain reac-
tion (RT-PCR). Her total RNA was isolated from
formalin-fixed, paraffin-embedded tissue sections (FFPE
tissue) using a Recover All Total Nucleic Acid Isolation
kit (Ambion, USA). The extracted RNA was then trea-
ted with RNase-free DNase I before cDNA preparation.
Her RNA was then reverse transcribed into cDNA using
the Superscript First strand synthesis system (Invitro-
gen). A total of 500 nanograms of her total RNA was
briefly reverse transcribed into cDNA using random
hexamers at 42°C for 50 min, which was then followed
by 70°C for 15 min.
The synthesized cDNA from our patient was then trea-
ted with RNase H for 20 min at 37°C to remove the RNA-
DNA hybrids. A total of 2 μl from the reaction was PCR
amplified using EWS 22.3 forward primer (5’-TCC TAC
AGC CAA GCT CCA AGT C-3’) and FLI1 11.3 reverse
primer (5’-ACT CCC CGT TGG TCC CCT CC-3’)i na
20-μl reaction volume containing 10 pmol each of the for-
ward and reverse primers, for a total of 20 μl PCR master
mix (Qiagen, Germany). PCR conditions from her samples
were as follows: 35 cycles of 94°C for 30 s, 65°C for 1 min,
Figure 1 Oblique sagittal view of the pelvis via computed
tomography scan showing a large heterogeneous mass in the
upper vagina causing obstruction of the os and leading to
hydrometra. The urinary bladder is displaced anteriorly and a self-
retaining catheter is seen within it.
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checked in 10% polyacrylamide gel and stained with silver
nitrate. Two positive controls (EWS-FLI1 type-I and type-
II PCR product cloned into pTZ57R/T vector) and one
water-only (no cDNA) negative control were included in
each run. To check the quality and integrity of the cDNA,
FOXO1A was amplified as a housekeeping gene (FKH-F:
5’ CAT CCC CTT CTC CAA GAT CA 3’;F K H - R :5 ’
GCT GCC AAG AAG AAA GCA TC 3’).
Meanwhile, our patient’s pathological findings were
achieved through conventional H&E. The stained sections
showed a malignant round cell tumor, with undifferen-
tiated cells arranged in a diffuse pattern and exhibiting
focal rosettes. The cells were found to be small with scanty
cytoplasm and uniform chromatin. On IHC, her tumor
cells were diffusely positive for vimentin and showed
membranous positivity for MIC2, along with areas of
BCL2 and FLI-1 positivity. On the other hand, her tests
for CK, EMA, desmin, Myo D-1, Myogenin and SMA
were negative. (Figures 2A, B, C, D, E).
W et h e no f f e r e do u rp a t i e n tad i a g n o s i so fP N E T ,
although we also considered a close differential diagno-
sis of synovial sarcoma. In view of the uncommon loca-
tion of her mass, molecular studies were recommended.
On molecular analysis using the RT-PCR technique,
t (11; 22) (q24; q12) (EWSR1-FLI1) turned out positive,
thus confirming the diagnosis of primary Ewing’ss a r -
coma or PNET of the vagina. (Figure 3). Her SYT-SSX1
and SYT-SSX2 analysis was negative. Her bone marrow
examination result, meanwhile, was normal.
Following our diagnosis of primary Ewing’s sarcoma or
PNET of the vagina, our patient was subjected to combi-
nation chemotherapy for 9 weeks based on institutional
protocol for Ewing’s family of tumors (EFT) 2001, includ-
ing drugs such as vincristine (1.5 mg/m
2), ifosamide
(2.0 g/m
2), etoposide (100 mg/m
2), cyclophosphamide
Figure 2 Microcopic findings of a primary vaginal Ewing’s sarcoma and/or primitive neuroectodermal tumour. (A) Sheets of undifferentiated
malignant round cells, Hematoxylin and Eosin, ×200 magnification. (B) Tumor cells displaying membranous positivity with MIC2/CD99. DAB × 400.
(C) Tumor cells displaying FLI1 positivity, DAB ×400. (D) Tumor cells negative for cytokeratin, DAB ×400. (E) Areas displaying BCL2 positivity, DAB ×400.
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2), doxorubicin (60 mg/m
2), and actinomycin
(1.0 mg/m
2). The induction phase was followed by local
treatment with radiotherapy (RT), during which our
patient was found to be clinicoradiologically free of the
disease. Following this, she was put on maintenance che-
motherapy, including the aforementioned drugs. She was
also put on regular follow-up examinations for the next
seven months.
Discussion
Ewing’s sarcoma and primitive neuroectodermal tumor
(PNET) are defined as round cell sarcomas that show
varying degrees of neuroectodermal differentiation and
are identified by light microscopy, IHC and electron
microscopy. While Ewing’s sarcoma lacks neuroectoder-
mal differentiation, a PNET possesses it [9]. Both, how-
ever, are characterized by a t(11; 22) (q24; q12)
chromosomal translocation leading to a chimeric tran-
script EWS-FLI1 in 85% of reported cases. Its presence
thus confirms a diagnosis of primary Ewing’s sarcoma/
PNET, especially at unusual sites where the index of
suspicion is low [10].
Primary extraosseous Ewing’s sarcoma/PNET is rarely
diagnosed in the genital tract of women. It rarely occurs
in the vagina, as in the case we describe in this report.
Previously documented cases involved the presence of
mass and associated pain [4-8] (Table 1).
Our patient’s biopsy revealed a malignant round cell
tumor below an unremarkable mucosa. In view of this
location, differential diagnoses included poorly differen-
tiated carcinoma such as a small cell carcinoma and round
cell sarcomas like a Ewing’s sarcoma/PNET, monophasic
synovial, and rhabdomyosarcoma. The presence of uni-
form cells with focal rosettes, however, made a diagnosis
of rhabdomyosarcoma less likely. On IHC, diffuse positiv-
ity with vimentin and lack of CK, EMA, CK7 ruled out a
carcinoma. Diffuse membranous MIC2 positivity was
more in keeping with a Ewing’s sarcoma/PNET than neu-
roendocrine carcinoma and a synovial sarcoma that also
shows MIC2 and cytoplasmic expression.
Meanwhile, MIC2 positivity is also identified in rhab-
domyosarcomas and lymphomas. However, the lack
of desmin, myogenin and MyoD-1 ruled out rhabdo-
myosarcoma, while LCA negativity ruled out a diagnosis
of lymphoma. In addition, FLI-1 positivity was also help-
ful even though its expression is noted in lymphomas,
rhabdomyosarcomas and synovial sarcomas [11]. While
the former two were ruled out, additional bcl-2 positiv-
ity was more consistent with a diagnosis of synovial sar-
coma. At the same time, bcl-2 positivity has also been
Figure 3 Polymerase chain reaction analysis of EWS-FLI1 translocation using EWS and FLI1 primers. Reactions were subjected to
electrophoresis on a 10% polyacrylamide gel and stained with silver nitrate. Lane M: the DNA size markers in base pairs (bp); Lane 1: Polymerase
chane reaction run was performed with cDNA from sample; Lane 2: Positive control DNA (pTZ57R/T-EWS/FLI1-330 bp); Lane 3: Positive control
DNA (pTZ57R/T-EWS/FLI1-394 bp); Lane 4: PCR amplification without DNA template to rule out contamination.
Table 1 Literature review of 6 cases of primary vaginal Ewing’s sarcoma/primitive neuroectodemal tumor (PNET)
Sr No Study Age T-size IHC profile Mol. Results Treatment Outcome
1 Vang et al. [4] (2000) 35 3 cm. VIM+, MIC2+ EWS/FLI1+ WE +CT+RT FOD (19 mo)
2 Farley et al. [5](2000) 35 4 cm. MIC2+ NP CT+EBRT+ICBT FOD (48 mo)
3 Petkovic et al. [6](2002) 45 9 cm. MIC2+ NP CT+EBRT+ICBT AWD (18 mo)
4 Liao et al. [7](2004) 30 5 cm. VIM+, MIC2+, FLI1+, synaptophysin+,
2neuron specific enolase (NSE)+, S-100+
NP TAH, BSO+ CT FOD (36 mo)
5 McCluggage et al. [8] (2007) 40 8 cm. VIM+, MIC2+, FLI1- EWS- ∞∞
6 Present case (2009) 17 10 cm. VIM+, MIC2+, FLI1+, BCL2+ EWSR1/FLI1+ CT+Local RT On Follow-up
T-size, tumor size in largest dimension; IHC, immunohistochemistry; VIM, Vimentin; Mol., molecular; NK, Not Known: +, positive; -, negative; NP, Not Performed; ∞,
Details could not be procured; WE, wide excision; CT, Chemotherapy; EBRT, external beam radiotherapy; ICBT, intracavitatory brachytherapy; TAH+BSO, total
abdominal hysterectomy + bilateral salpingoopherectomy; FOD, free of disease; mo, months; AWD, alive with disease.
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nosis of Ewing’s sarcoma/PNET was confirmed on RT-
PCR with positive EWSR1-FLI1 results. SYT-SSX for a
synovial sarcoma was negative. In five cases documented
so far, only one case of vaginal Ewing’s sarcoma/PNET
was confirmed through molecular analysis [4].
The value of identifying Ewing’s sarcoma/PNET as the
correct diagnosis is necessary in coming up with specific
treatment for patients. Despite its aggressive behavior at
osseous sites, this tumor responds to specific che-
motherapy. All the cases documented so far have been
subjected to chemotherapy with options of surgery ran-
ging from wide excision to total abdominal hysterect-
omy [5-8]. Adjuvant RT has also been offered in two
cases [5,6]. After being diagnosed with Ewing’s sarcoma/
PNET, for the next seven months our patient completed
the induction phase of chemotherapy and underwent
local RT, during which she was found to be disease-free.
She is presently on maintenance chemotherapy.
The treatment outcome for patients with primary
vaginal Ewing’s sarcoma/PNET has been favorable in so
far as documented cases are concerned. No metastasis
or causalities have also been reported [4-7]. In contrast,
a neuroendocrine carcinoma, more commonly in post-
menopausal women, has a relatively downhill course.
Despite a size of ≥ 5 cm in three out of five documented
cases, a superficial, mucosal location and a relatively
younger age of occurrence are possible reasons behind a
relatively better treatment outcome [6-8].
Conclusion
Our case report describes a rare site of primary vaginal
Ewing’s sarcoma/PNET in the youngest patient known
so far. It reinforces the value of IHC, including membra-
nous MIC2 positivity and with molecular analysis, in the
objective identification of this sarcoma at unusual sites
like the vagina. Correctly identifying tumor type enables
clinicians to identify specific CT procedures as treat-
ment mainstay. The identification and documentation of
more cases with a clinicopathological index of suspicion,
the confirmation of diagnosis using ancillary techniques,
and the management and follow-up results would
greatly contribute to the existing knowledge of diagnosis
and outcome of PNETs developing at unusual sites.
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